SB202190 (FHPI)

For research use only.

Catalog No.S1077

89 publications

SB202190 (FHPI) Chemical Structure

CAS No. 152121-30-7

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 134 In stock
USD 147 In stock
USD 370 In stock
USD 637 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's SB202190 (FHPI) has been cited by 89 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.
Targets
Ferroptosis [11]
()
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 M2HWcWZ2dmO2aX;uJGF{e2G7 M1XLdlI2KM7:TR?= NH3KWJc{OCCvaX6= M1XqUmROW00EoB?= NYr1VodH[XS2ZX71ZZRmeyC2aHWgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJI9nKGiERD2yJIlvKHKnc4DvcpNqfmVidH:gSGE> NY\HWWFvOjZ{MkOyOVE>
MDA-MB-231 MVTGeY5kfGmxbjDBd5NigQ>? MYiyJO69VQ>? M1H4RVI1KGh? NImyNI5t\XO|ZX7ld{BES0x{IHnu[JVkfGmxbjDifUBVVkcQsR?= MYOyOlExODh2OB?=
rBMSCs MVrGeY5kfGmxbjDBd5NigQ>? NVfh[Zg4OTBizszN NInFbVMzNjViaB?= M1fifoRmeHKnc4Pld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFXST{BidmRicEO4 MlvnNlYxPTN{Nk[=
MG63 MXTGeY5kfGmxbjDBd5NigQ>? NI\1RZAyOC9{MD:zNEDPxE1? MXyyOEBp MXvzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy NVy1V2RZOjV7OUizNVI>
MG63 NVHXR3hrSXCxcITvd4l{KEG|c3H5 NWS0dXJDOTBxMkCvN|Ah|ryP NHLaNGwzPCCq NGrBdY5{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnZDD0bIUh[XCxcITvd4l{KHKjdHWgc4YhVUd4MzDpcoR2[2WmIHL5JGNlS2x{ NXLySZJQOjV7OUizNVI>
HTSMCs NGP0eppHfW6ldHnvckBCe3OjeR?= MVOwMlEwOS9zMDFOwG0> NXzYWY45OSCq NUTacZNLcW6qaXLpeIVlKEORUl2tNk1qdmS3Y3XkJGhQNTFicILveIVqdiCuZY\lcJMh[W6mIH3SUmEh\XiycnXzd4lwdg>? NVfrTWZ2OjV7MkG0OlQ>
MIA PaCa-2 NXjmblNoTnWwY4Tpc44hSXO|YYm= MWCyNOKh|ryP MX[yOEBp NY\JWotremWmdXPl[EBt[WO2YYTlJIFk[3WvdXzheIlwdiCrbjDjc41jcW6jdHnvckB4cXSqIHLveIghOi2GRzDhcoQhTC2jbHzvd4XDqA>? M{KwU|I2QDh6NEi5
MIA PaCa-2 M4\yfmZ2dmO2aX;uJGF{e2G7 NI\1b5IzOMLizszN Mn\NNlQhcA>? M3jwd5Jme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u NXnhOZhVOjV6OEi0PFk>
BxPC-3 M1vT[WZ2dmO2aX;uJGF{e2G7 MWeyNOKh|ryP NYjSdHdHOjRiaB?= MmTJdoV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y|rFicILveIVqdiCjY3P1cZVt[XSrb36= MYCyOVg5QDR6OR?=
AsPC-1 NGXhXJZHfW6ldHnvckBCe3OjeR?= MYGyNOKh|ryP NHnlW4QzPCCq M4[xO5Jme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u Ml33NlU5QDh2OEm=
MIA PaCa-2 NX7EN3JGTnWwY4Tpc44hSXO|YYm= NXf0T5RROjEEoN88US=> NFPUfIYzPCCq NYTnc3FR\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEB4cGWwIHPvcYJqdmWmIIfpeIgh\2y3Y3;z[UBidmGub3fz NUjGVo91OjV6OEi0PFk>
MIA PaCa-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG3V2YzOMLizszN M4H1fVIhcA>? MlXKd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm NUHzeJhJOjV6OEi0PFk>
BxPC-3 NYD3ZWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKyNOKh|ryP MofVNkBp M2LjSZNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? M36wU|I2QDh6NEi5
AsPC-1 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\TNlDDqM7:TR?= MkP6NkBp Mo\Qd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm NWP0dVhWOjV6OEi0PFk>
HEY MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\RNlDDqM7:TR?= MUCyJIg> NISycIJ{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? MUeyOVg5QDR6OR?=
OVCAR-3 M{ezUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rSVVIxyqEQvF2= NICyWnUzKGh? Mmm0d4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm M1rWOFI2QDh6NEi5
SK-OV-3 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHTNlDDqM7:TR?= NV:0[m1XOiCq M1K0SpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? M3;wSlI2QDh6NEi5
MH7A  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[1NlQhcA>? NVfINmJKemWrbn\vdoNmeyC2aHWgbY5pcWKrdH;yfUBm\m[nY4TzJI9nKFiDTh?= M1PqdVI2QDZ{OU[2
MH7A  MmnURZBweHSxc3nzJGF{e2G7 MVuyOUDPxE1? MYSyOEBp NXj2R4kyemW4ZYLz[ZMh[2WubDDjfYNt\SCjcoLld5QhcW6mdXPl[EBjgSC[QV6gZY5lKGOjdYPl[EBieG:ydH;zbZMhd2ZiY3XscJMhfmmjIHHjeIl3[XSrb36gc4YhUk6N MlzmNlU5PjJ7Nk[=
SCC25 NYHIeYJlTnWwY4Tpc44hSXO|YYm= MWOyNEDPxE1? MYGyOEBp Ml[5bY5kemWjc3XzJIF2fG:yaHHnfUBt\X[nbB?= NHrPN|gzPTh|NESwNC=>
HaCaT  MnnoSpVv[3Srb36gRZN{[Xl? NYjTelNoPSEEtV2= MnnzNlQhcA>? MXTpcohq[mm2czDJSm4u|rNvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=> MlHWNlU5OzR|NUO=
HaCaT  NV;yfIlnTnWwY4Tpc44hSXO|YYm= M3fSWlUhyrWP M{HYcFI1KGh? NGPGUJZqdmirYnn0d{BKTk5vzsGtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>? MmjTNlU5OzR|NUO=
HPAEpiCs  MV3GeY5kfGmxbjDBd5NigQ>? Mk\nNU8{NzFyIN88US=> M3HRVlEhcA>? M1Lx[pJm\HWlZYOgV|FRNWmwZIXj[YQhUUODTT2xJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHl? MoPvNlU4OzR7MEC=
HPAEpiCs MYLGeY5kfGmxbjDBd5NigQ>? M4nLe|EwOy9zMDFOwG0> NXPI[5JsOSCq MVvpcohq[mm2czDTNXAue3SrbYXsZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wIDFCpC=> NXHIRoNpOjV5M{S5NFA>
HPAEpiCs NVvVdI9RTnWwY4Tpc44hSXO|YYm= Mn7VNU8{NzFyIN88US=> NFL0[XoyKGh? NFzoOItqdmirYnn0d{BUOVBidHnt[U1l\XCnbnTlcpRtgSC|dHnteYxifGWmIHOtTpVvKHCqb4PwbI9zgWyjdHnvci=> NYP4[JpWOjV5M{S5NFA>
K562 MXfGeY5kfGmxbjDBd5NigQ>? NU\rT2I1OTEEoN88US=> NITFSJgyyqCq Mmj6SG1UVw>? M3;aSolvcGmkaYTzJJF2cW6jY4LpcoUucW6mdXPl[EBxOzhiTVHQT{BxcG:|cHjvdplt[XSrb36= NYrJNXVmOjV4OESwOFM>
PANC-1 NXXye4FTTnWwY4Tpc44hSXO|YYm= NWryfllnOTBizszN NF:xdocyKGh? Mn3N[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB? Mnf4NlU3OzJ{MkK=
BxPC-3 NHXS[2ZHfW6ldHnvckBCe3OjeR?= M1nKfVExKM7:TR?= M3rtWlEhcA>? MnX5[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB? MoH2NlU3OzJ{MkK=
K562  NFnxdVZHfW6ldHnvckBCe3OjeR?= NEnwPGcxNjJ3LUGg{txO NG\5SJkzPCCq NFTKepV{fXCycnXzd4V{KHKnc4\ldoF1em:uLXnu[JVk\WRiSELBXEBxcG:|cHjvdplt[XSrb36= NXi3WW9rOjV4MUmzPVI>
THP-1 MUfGeY5kfGmxbjDBd5NigQ>? NI\pUXA2KML3TR?= NFHJcXMzKGh? M3u1dpNq\26rZnnjZY51dHliYYT0[Y52[XSnczDz[YNz\XSrb36gc4YhUUxvMd8xJIlv\HWlZXSgZpkhOjeRSFPoc4wheGy3czDGV2wuOcLi M1\qRlI2PTl6Nk[x
WB MkTCSpVv[3Srb36gRZN{[Xl? NE\4TIszOOLCid88UeKh MlOwN|DjiImvaX6= NFW2OG9l\WO{ZXHz[ZMhfGinIFzQV{0hd3JiTGTBMYlv\HWlZXSgTWwuPiCjbnSgWG5HNc7zwrDwdo9lfWO2aX;u MXKyOVU{ODZ6Mh?=
RAW 264.7 MkDpSpVv[3Srb36gRZN{[Xl? NVjFNYRIOTEEoN88US=> NGTmTWU{OOLCiX3pci=> M2TTbYlv\HWlZYOgZ4hiemGldHXybZN1cWNidnHjeY9t[XSrb36gc4YhV0O|wrC= M3XNVlI2PDZzM{m5
RAW 264.7 M1PZNmZ2dmO2aX;uJGF{e2G7 M13LdVExyqEQvF2= Mom1N|DjiImvaX6= NWm5e5Vp[XS2ZX71ZZRmeyC2aHWg[YZn\WO2czDv[kBQWEdib36gc5N1\W:lbHHzeEBz\XS{YXP0bY9v NIKxR5UzPTR4MUO5PS=>
HaCaT  NFr0V4ZHfW6ldHnvckBCe3OjeR?= MV60NOKh|ryP MWOzMVI1KGh? NE[zbIZFVVOR M2rtOJJm\HWlZYOgeIhmKGGlY4XteYxifGmxbjDv[kBbVy1z MVWyOVQ{PTR6NR?=
H9c2 M{O2XmZ2dmO2aX;uJGF{e2G7 MVi1NOKh|ryPwrC= MX2xNkBp NXu1PYF{emWmdXPld{BNTEhicnXs[YF{\SCjbnSgUW1RKGyxc4O= NUPMZWRYOjV{NEW4NVg>
HSCs NEDmRmxCeG:ydH;zbZMhSXO|YYm= Ml\iNlUh|ryP MXGyOOKhcA>? MVXzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN? NHfQd|gzPDl4MUm1NC=>
THP-1 NXPPcFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTVbHQ4OiCq MknySG1UVw>? M3jN[2lEPTB;ND63{txO NXjUdmh2OjR6MUWwPFc>
MDDCs NHvRcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfUWm86PzJiaB?= M1;pUWROW09? NFTDSWxKSzVyMj63{txO NIPCU2MzPDhzNUC4Oy=>
MDDCs MoXJSpVv[3Srb36gRZN{[Xl? NUfj[Vh6OC1zNTFOwG0> M{nvUlQ5KGh? Mme2SG1UVw>? NV;DOI44e3WycILld5NmeyCLRl6t{tEh[W6mIFnQMVExKHC{b3T1Z5Rqd28EoB?= M4e4UlI1QDF3MEi3
MDDCs MWPGeY5kfGmxbjDBd5NigQ>? MXiwMVE2KM7:TR?= NGP3Vm01QCCq M33LRmROW09? NYXZR3ZHcW6qaXLpeJMhVUmSLUHhMEBOUVBvMXKgZY5lKFKDTmTFV{Bxem:mdXP0bY9v NYjHfnREOjR6MUWwPFc>
MDDCs MVfGeY5kfGmxbjDBd5NigQ>? NFrVSGwyOCEQvF2= NYG5OYFwOy53IHi= NIe5U4NFVVOR NVHJfoF4[myxY3vzJGVDV1ZiR2CsJIJ2fCCwb4SgWnNXKEdibXXkbYF1\WRiZX70dpkhcW62bzDoeY1idiCPRFTDdy=> M2DLSlI1QDF3MEi3
macrophages NFTT[lNHfW6ldHnvckBCe3OjeR?= MljINgKBkc7:TR?= MoXDOE426oDLaB?= NGLPNVlkd22ybHX0[Yx6KGmwaHnibZR{KE2WLVnJTU1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiTl[t{tpD M3nvdFI1QDB6NkOz
PDL  MXjGeY5kfGmxbjDBd5NigQ>? MnnGNlDDqM7:TdMg M1vxNlMxKG2rbh?= MWHEUXNQ NYXlfmF4e2mpbnnmbYNidnSueTDpcohq[mm2czD0bIUhfGWwc3ns[UBnd3KlZT3t[YRq[XSnZDDCUXAuOiCneIDy[ZN{cW:w MXeyOFU3OTB6MR?=
AGS MXfGeY5kfGmxbjDBd5NigQ>? NX\3cpJLPSEQvF2= MlniN|AhdWmw M{LWcpN2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v M{TYfVI1PTR5OEe4
H520 MmjSSpVv[3Srb36gRZN{[Xl? MXqxNOKhyrWP MV[xJIg> MX3EUXNQ NGfqOpJl\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz M3TXVlI1PTNyNEe1
H1703 MnfFSpVv[3Srb36gRZN{[Xl? NHz4dYoyOMLiwsXN NV2zbplvOSCq NXXPfHRPTE2VTx?= Mn7O[IVkemWjc3XzJJRp\SCyZX3leJJmgGWmLXnu[JVk\WRiTWPINkBuWk6DIHHu[EBxem:2ZXnuJIxmfmWucx?= MkmwNlQ2OzB2N{W=
H520 NIrtVG5HfW6ldHnvckBCe3OjeR?= NXv4Ro5VOTEEoNM1US=> NE\tUXUyOiCq MV3EUXNQ NGXxOXRqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm= MX:yOFU{ODR5NR?=
H1703 M1u2SmZ2dmO2aX;uJGF{e2G7 MnzKNVDDqML3TR?= MXixNkBp NI[5bGFFVVOR NWHmd2lTcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5 NWC1fGEyOjR3M{C0O|U>
H520 NXrySpJCTnWwY4Tpc44hSXO|YYm= MV[xNOKhyrWP NGLoNJI3KGh? NUnnd3p3TE2VTx?= NU\rV3Zne2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l NHHzco0zPDV|MES3OS=>
H1703 MlfaSpVv[3Srb36gRZN{[Xl? MYqxNOKhyrWP M1;GUlYhcA>? M1HOc2ROW09? NGHFSlN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhdGW4ZXzzJI9nKHWkaYH1bZRqdi2lb37qeYdifGWmIF3TTFIhcW5icHXt[ZRz\XinZD30doVifGWmwrDj[YxtKGyrbnW= MYeyOFU{ODR5NR?=
MC3T3-E1 NF3zV4hHfW6ldHnvckBCe3OjeR?= M2XIcFAvOy9|L{OwJO69VQ>? NGXqbWMyKGh? MoD0ZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{wrC= MlvaNlQ2ODJ4OU[=
MC3T3-E1 NYDIPJNmTnWwY4Tpc44hSXO|YYm= NXm3eHh1OzBizszN MYqxJIg> MWrheJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?= Mn6zNlQ2ODJ4OU[=
HUVECs  NXfTN|FiTnWwY4Tpc44hSXO|YYm= NHrFTmMyOMLiwsXN MlTBNUBp MlXobY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiQ2jDUFEheHKxZIXjeIlwdg>? NVHNfZpoOjR2OEe5OlQ>
AGS  NGTXRW5HfW6ldHnvckBCe3OjeR?= NHH6S2cyOMLiwsXN M3fyT|MxyqCvaX6= MUnpcohq[mm2czDJUE0y|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>? M37zb|I1PDd7Nkix
MKN-45 NVHleVNoTnWwY4Tpc44hSXO|YYm= Mm\UNVDDqML3TR?= NEmz[mE{OMLibXnu NH\T[phqdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB|OB?= NETzbZEzPDR5OU[4NS=>
AGS  NVTvdohRTnWwY4Tpc44hSXO|YYm= M{DPWFExyqEEtV2= MYOzNOKhdWmw NYjzU4Vp[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25? M3nZ[VI1PDd7Nkix
MKN-45 MonVSpVv[3Srb36gRZN{[Xl? NX3Dbo8yOTEEoNM1US=> MV:zNOKhdWmw MUDheJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=> M{XOb|I1PDd7Nkix
AGS  NHLtfY9HfW6ldHnvckBCe3OjeR?= MU[xNOKhyrWP MmXHN|DDqG2rbh?= Mof1d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiSXytNe6zNWmwZIXj[YQhVU2SMjDhcoQhVU2SOTDtVm5CKGW6cILld5Nqd25? NUn2bY85OjR2N{m2PFE>
MKN-45 M2HNbGZ2dmO2aX;uJGF{e2G7 MYmxNOKhyrWP Mk\TN|DDqG2rbh?= NInrSZV{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?= M3m4VVI1PDd7Nkix
DCs Mm\wSpVv[3Srb36gRZN{[Xl? MWCyNOKh|ryP NWPuNIVkOcLiaB?= NI\0PXhl\WO{ZXHz[ZMhUUxvMUKgdJJw\HWldHnvci=> NWTCfpo{OjR2M{S2N|Y>
HUVEC  MmHpSpVv[3Srb36gRZN{[Xl? NIjq[oQzOCEQvH5CpC=> MYK1JIg> M{frUWROW09? MnvZdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= M2XCWlI1OTh7ME[y
A 549 NWm3OFF2TnWwY4Tpc44hSXO|YYm= NX7ZSmpFPTBizszN MWOxJIg> MYLk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKEmOLUlCpC=> M3yxW|I1OTd7Nki4
H520  MVHGeY5kfGmxbjDBd5NigQ>? NH6wdZA2NzFyIN88US=> MWGxJIg> NETYc4FFVVOR MoW3[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy= NUHvdVdROjRzM{i5NFM>
H1703  M{jlPGZ2dmO2aX;uJGF{e2G7 NIrOd|c2NzFyIN88US=> MoDlNUBp MV\EUXNQ MWHk[YNz\WG|ZYOgUXNJOiCycn;0[YlvKGG|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?= M{\6SFI1OTN6OUCz
H520  MmnISpVv[3Srb36gRZN{[Xl? NYfCOW1kOTEEoNM1US=> NFjnT44yOiCq M4PrPWROW09? MlPV[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM> NXf3R|lMOjRzM{i5NFM>
H1703  M3\yRmZ2dmO2aX;uJGF{e2G7 M{n0UVExyqEEtV2= NX7HTmVyOTJiaB?= NIr6emlFVVOR NUPCS|lX\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN? M{HR[lI1OTN6OUCz
MCF-7  M1qwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILxbZIyOMLizszN MmLZNlTDqGh? NFvRVplqdmirYnn0d{B1cGViQ2KxNFgucW6mdXPl[EBk\WyuIHTlZZRp M{\HeFI1OTJ6OEWz
HPAEpiCs MXXGeY5kfGmxbjDBd5NigQ>? M2DHXlAvOS9zL{GwJO69VQ>? MWexJIg> MojJbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiY2DMRVLDqHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdg>? MnPXNlQxPjlzNUi=
podocytes MXPGeY5kfGmxbjDBd5NigQ>? M1nHUlExyqEQvF2= NFXqVmcyKGh? MXHpcohq[mm2czDUS2bPujFvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFugZY5lKEW{a{GvNuKh NVjvZ5hPOjRyM{[yNVI>
MCF-7 NFvlSZFHfW6ldHnvckBCe3OjeR?= M3jtSVExyqEQvF2= NYrlSWkzOSCq NInxXo5FVVOR MkXHdoVlfWOnczD0bIUhX0FvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBxOzhiTVHQTy=> MoDsNlQxOTlyOUC=
MCF-7 NXXRc45JTnWwY4Tpc44hSXO|YYm= NWPkWFRTOTEEoN88US=> MlvFNlQhcA>? MlexSG1UVw>? NVL2NWZNcW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> MXGyOFAyQTB7MB?=
HAPI NEO5VmJHfW6ldHnvckBCe3OjeR?= NULPeWJMOTBxMkCvOFDDqM7:TR?= MmTBNUBp M3X5TIlvcGmkaYTzJHRETERvaX7keYNm\CCyM{ivTm5MKE2DUFugdIhwe3Cqb4L5cIF1cW:w MYKyN|k3QTF{MB?=
HAPI M3frO2Z2dmO2aX;uJGF{e2G7 MYOyNOKh|ryPwrC= NH6zfZcyKGh? NIDpUHNFVVOR NHvPeGNifHSnboXheIV{KFSFRFStbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGmQT2OgZY5lKHC{b3T1Z5Rqd25? NV3iWVVROjN7NkmxNlA>
HepG2 MlvrSpVv[3Srb36gRZN{[Xl? M2L1SVM2OCCwTR?= Mn7JNlQhcA>? NFqwSJRqdmirYnn0d{B1cGViZHXneYVtcW5vaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFu= MU[yN|k{OzF7OB?=
AGS  MWHGeY5kfGmxbjDBd5NigQ>? MVOxNOKh|ryP M3rSNlMxKG2rbh?= NGO5V5RqdmirYnn0d{Bk[XOyYYPlMVMh[WO2aY\heIlwdiCjbnSgbY5pcWKrdHnvckBw\iCHUlu= NFS4cJIzOzh3MEm5OC=>
HepG2 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMVUxKM7:TR?= NXvPVlNGPDhiaB?= NVXjcYpxcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MnXZNlM5ODd3MEi=
BEL7404 NUftWlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6wMVUxKM7:TR?= NFXqNWY1QCCq M1T0[IlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MmroNlM5ODd3MEi=
HL7702 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LhXlAuPTBizszN NVz3b3FIPDhiaB?= MlrhbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NEDPW4EzOzhyN{WwPC=>
HepG2 NEPLPVhHfW6ldHnvckBCe3OjeR?= NGXL[XYxNTVyIN88US=> M3jObFI1KGh? NX25NFFwcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDwN|gh\G:5boP0doVidSCycn;0[YlveyCPQWDLRXBMOixiQWTGNkwhVVONMTDhcoQhUFOSMkegbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NG\wZnQzOzhyN{WwPC=>
BEAS-2B NFXyZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LzSVExKM7:TR?= MnL2N|AhdWmw M33hTZJmfmW{c3XzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IFjDTS=> NHPFRlIzOzd6NECzOC=>
BEAS-2B MkT4R5l1d3SxeHn0fUBCe3OjeR?= NF7VTWIyOCEQvF2= MYezNEBucW5? NHuwUVVqdmirYnn0[YQhfGinIHnuZ5Jm[XOnIHnuJGxFUCCjbnSgTWwuQCCneIDy[ZN{cW:w MXOyN|c5PDB|NB?=
BEAS-2B MnvDSpVv[3Srb36gRZN{[Xl? MmrTNVAh|ryP M2nkSFMxKG2rbh?= MXTk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iClYYPwZZNmNTNuIFLh[EBidmRiZnHz M1XKN|I{Pzh2MEO0
H9c2  MXzGeY5kfGmxbjDBd5NigQ>? NVjE[ZJlOC5yMT:wMlEwOSEQvF2= M{LiUVEhcA>? NGOwN5lifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36sJI1TVkFibHX2[Yx{NCCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm= MXiyN|c4PDJ3Mh?=
H9c2  M2PlR2Z2dmO2aX;uJGF{e2G7 NFX1dXYyKM7:TR?= NYC3S5FyOSCq Mmq0doVlfWOnczDUUmYu|rFiZHny[YN1dHlic4TpcZVt[XSnZDDwN|ghVUGSSzDwbI9{eGixconsZZRqd25? M3HmUVI{Pzd2MkWy
U937 M1fGRmZ2dmO2aX;uJGF{e2G7 NVjmcmo6OTEEoN88UeKh MVmxJIg> MXzhZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6|Y4LpdJRqd26jbDDs[ZZmdHN? MWSyN|cxPzN6Nx?=
U937 M3G3ZmZ2dmO2aX;uJGF{e2G7 MmXUNVDDqM7:TdMg M1HvN|EhcA>? NYHIW5Ro[WK{b3fheIV{KGOjZn\lbY5mNWmwZIXj[YQhVUuSLUGg[I94di2{ZXf1cIF1cW:wIHHu[EBRWDKDY98xJJVxNXKnZ4XsZZRqd25? NIjt[HAzOzdyN{O4Oy=>
U937 NWHQ[VBNTnWwY4Tpc44hSXO|YYm= NFzlfnkyOMLizszNxsA> NUnJeIQ{OSCq MmfXd5VxeHKnc4Pld{BkNUq3bjDhcoQhS1KHQjDwbI9{eGixconsZZRqd25iaX6gZ4Fn\mWrbnWteJJm[XSnZDDj[Yxte8Li NFjoWG4zOzdyN{O4Oy=>
A549 NYH2NoE6TnWwY4Tpc44hSXO|YYm= MmfsNE4{NzNxM{Cg{txO M1nTdlEhcA>? NWDBVZFLe2mpbnnmbYNidnSueTDheJRmdnWjdHXzJGFVWM7|Uz3t[YRq[XSnZDDDU3guOiCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25iYX7kJJBzd22xdHXyJIFkfGm4aYT5xsA> NUCwUpdVOjN4OEC2O|Q>
A549 NES2OYtHfW6ldHnvckBCe3OjeR?= MVWxNOKh|ryPwrC= MkLQNE0{OCCvaX6= NYHDWHFUcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgdFQzN3B2NDDNRXBMKGGwZDDwN|ghVUGSSzDwbI9{eGixconsZZRqd25? NHPrUJozOzZ6ME[3OC=>
A549 NHTDUJVHfW6ldHnvckBCe3OjeR?= NEXMWG4yOMLizszNxsA> MoH1NUBp NFHtOGhqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm= M3zYSlI{PjhyNke0
A549 NX3iU4ljTnWwY4Tpc44hSXO|YYm= NVPSeGJIOTEEoN88UeKh MmjNNUBp M{Oxb5Jm\HWlZYOgRXRR|rOVLYP0bY12dGG2ZXSgZ3BNSTJicHjvd5Bpd3K7bHH0bY9vyqB? NFXBXGgzOzZ6ME[3OC=>
A549 MXLGeY5kfGmxbjDBd5NigQ>? NGDjd3YyOMLizszNxsA> NUPRUWtpOSCq MoPadoVlfWOnczDBWHDPu1NvZX7oZY5k\WRiZX76fY1ifGmlIHHjeIl3cXS7IH;mJINRVEF{wrC= MVuyN|Y5ODZ5NB?=
PC12 NI\pVplHfW6ldHnvckBCe3OjeR?= NWXte3ZJOTBxMkCvOFAh|ryP M1nQ[lHDqGh? MUHpcohq[mm2czDKUmsh[W6mIICzPC=> MXuyN|U5PDN3Nx?=
HK-2 MlLnRZBweHSxc3nzJGF{e2G7 NIn6UWczOMLizszN MnfuNlQhcA>? MkTtbY5pcWKrdIOgSXJMKGGwZDDwN|hOSVCN NXP0eWN4OjN3NEOxOVE>
H9c2 NXu3W2VVTnWwY4Tpc44hSXO|YYm= MXKxxsDPxE1? NUjycpZ4OSCq MWXy[YR2[2W|IGTOSk3PuS2rbnT1Z4VlKE2PUD25JI1TVkFibHX2[Yx{KGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= M2jacFI{OzV|Nkm5
H9c2 M3WxUGZ2dmO2aX;uJGF{e2G7 MmX6NeKh|ryP M{j6SFEhcA>? MXry[YR2[2W|IGTOSk3PuS2nbnjhcoNm\CCDUD2xJJBzd22xdHXyJIFkfGm4aYT5 MV:yN|M2OzZ7OR?=
H1650  M4DZeWZ2dmO2aX;uJGF{e2G7 M370O|ExyqEQvF5CpC=> NHfYcJQyKGh? NWLLWmJwTE2VTx?= NWrZPZFG\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?= Mor4NlMzOjh4OU[=
H1703 MVLGeY5kfGmxbjDBd5NigQ>? MYmxNOKh|ryPwrC= MW[xJIg> NWjjS2JzTE2VTx?= MUDk[YNz\WG|ZYOgZo91cCCycn;0[YlvKGGwZDDtVm5CKGyndnXsd{Bw\iCHUlPDNUBqdiCyYXPsbZRigGWuLXX4dI9{\WUEoHPlcIx{ MYmyN|IzQDZ7Nh?=
H1650  NHi4[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKxNOKh|ryPwrC= MVmxJIg> M372OGROW09? MWPlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M1uwV|I{OjJ6Nkm2
H1703 NH;MW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuweJZoOTEEoN88UeKh M{PYRlEhcA>? M3m4Z2ROW09? MnPZ[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NF\NTIczOzJ{OE[5Oi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; 

PubMed: 26844273     


CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. 

pJNK1 / pJNK2 / JNK1 / JNK2 ; 

PubMed: 18222647     


A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described. 

26844273 18222647
Immunofluorescence
p-p38 / MMP9; 

PubMed: 24479681     


Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.

24479681
Growth inhibition assay
Cell viability ; 

PubMed: 26844273     


Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).

26844273
In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

- Collapse
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Water Insoluble
Ethanol '12 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%H2O
For best results, use promptly after mixing.
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A
Smiles C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID